https://www.sciencedaily.com/releases/2009/09/090917111639.htm
S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of...
rolescarcinogenesisesophageal
https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomapatritumab deruxtecandaiichi sankyoesophageal
https://pubmed.ncbi.nlm.nih.gov/15111177/?dopt=Abstract
Esophageal balloon cytology, endoscopy, mucosa 1.2% iodine stain, and multipoint biopsy may be the best approach for early diagnosis of esophageal carcinoma....
long termresultsoperationpatientsearly
https://www.pharmaceutical-technology.com/data-insights/motixafortide-acetate-biolinerx-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
Motixafortide acetate is under clinical development by BioLineRx and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomamotixafortide acetatebiolinerxesophagealescc
https://www.aging-us.com/figure/204028/f4
The MAP2K1 (MEK1) gene and ERK-MMP pathway were implicated in ESCC progression. Gene expression profiles in combination with gene ontology (GO) and KEGG...
squamous cellmicrornaprogressionesophageal
https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomatiragolumabgenentechusaesophageal
https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1237167/full
Esophageal carcinoma ranks as the sixth leading cause of cancer-related mortality globally, with esophageal squamous cell carcinoma (ESCC) being particularly...
alternative splicingfrontiersdatabaseesophagealsquamous
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1508285/full
BackgroundEarly esophageal basaloid squamous cell carcinoma (EBSCC) with ductal differentiation is a rare variant of esophageal cancer (EC), for which the cl...
case reportfrontiersrareearlyesophageal
https://www.spandidos-publications.com/10.3892/or.11.2.315/abstract
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
angiogenicswitchprecancerousstagehuman
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1408458/full
Background: Recently, a sum of trials of programmed cell death-1 (PD-1) inhibitors combined with chemotherapy have showed excellent efficacy compared to chem...
squamous cell carcinomafrontierspdinhibitorsadvanced
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.670051/full
Cell-in-cell structures (CICs) are defined as the special structures with one or more cells enclosed inside another one. Increasing data indicated that CICs ...
frontierssubtypebasedanalysiscell
https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomapfesophagealescc
https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-313747&utm_campaign=recommended-articles-pi
Botensilimab is under clinical development by Agenus and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomaagenusesophagealescclikelihood